LABORATORY AND CLINICAL STUDIES ON CEFPIRAMIDE (SM-1652)

• Published in: CHEMOTHERAPY Vol. 31; no. Supplement1; pp. 413 - 419
• Main Authors: KURIMURA, OSAMU, SASAKI, HIDEO, ARATANI, YOSHIHIKO, KANETO, EIJI, NISHIKAWA, YOSHIRO, KOSAKA, TSUTOMU, MARUYAMA, TAISUKE, TAKEMOTO, CHIKAO, MORITO, AKIRA, DOI, HIDEYUKI, YAGUCHI, HIROMI, YOKOTA, KAZUKO, SHIMONAKA, AKIKO, TAMURA, IKUO, SHIMASE, KOICHI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1983
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.31.Supplement1_413

Antimicrobial activity of cefpiramide (CPM, SM-1652) against Staphylococcus species was almost the same as that of cefotaxime and cefoperazone, but was inferior to that of cefazolin. To Streptococcus species the drug showed similar distribution of MICs to cefazolin and cefoperazone. Among Enterobacteriaceae, antimicrobial activity of the drug was relatively strong against Shigella and Salmonella, but in E. coli and Klebsiella species some strains showed resistance to the drug. To S. marcescens and Proteus species the activity of the drug was not so strong. On the contrary, against Pseudomonas species the drug showed much strong antibacterial activity compared with other cephems tested. Cefpiramide was administered to 4 cases of respiratory tract infection, and each one case of respiratory tract infection accompanied with urinary tract infection, pleurisy and fever of unknown origin. As the result, clinical response to cefpiramide was good in 5 cases, fair in 2 cases and poor in one case. No severe side effect was observed.